Unibest

Pharmaceutical intermediates

Tirzepatide Intermediates

3 pharmaceutical intermediates for Tirzepatide. Indication: Obstructive Sleep Apnea Syndrome (OSAS); Obesity; Overweight; Type 2 Diabetes Mellitus.

Submit a ProjectAll intermediates

About Tirzepatide

Originator
Eli Lilly
Indication
Obstructive Sleep Apnea Syndrome (OSAS); Obesity; Overweight; Type 2 Diabetes Mellitus
Approved Date
07/28/2023
NCE Patent
05/13/2027
DS/DP
01/05/2036

Available intermediates

3 intermediates currently listed for Tirzepatide. Request specifications, documentation or a quotation for any item below.

Tirzepatide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
AEEA-HCl134979-01-4//
AEEA-AEEA1143516-05-5//
Boc-AEEA-AEEA1069067-08-8//

Other programs under T

Tazemetostat HydrobromideTazobactam SodiumTegoprazanTenapanor HydrochlorideTeneligliptinTetrabenazineTezacaftorTianeptine sodium salt

Building toward Tirzepatide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →